ORIENT BIO Inc. (KRX:002630)
South Korea · Delayed Price · Currency is KRW 538.00
-12.00 (-2.18%)
Feb 5, 2026, 3:30 PM KST
ORIENT BIO Income Statement
Financials in millions KRW. Fiscal year is April - March.
Millions KRW. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '21 Dec 31, 2021 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
Operating Revenue | 59,091 | 52,020 | 37,214 | 30,373 | 25,625 | 109,019 |
Other Revenue | -0 | -0 | - | - | -0 | - |
| 59,091 | 52,020 | 37,214 | 30,373 | 25,625 | 109,019 | |
Revenue Growth (YoY) | 19.53% | 39.79% | 22.52% | 18.53% | -76.50% | 3.78% |
Cost of Revenue | 37,840 | 33,247 | 30,939 | 27,773 | 23,399 | 101,005 |
Gross Profit | 21,251 | 18,773 | 6,275 | 2,600 | 2,226 | 8,014 |
Selling, General & Admin | 11,120 | 9,359 | 11,988 | 10,004 | 10,140 | 14,884 |
Research & Development | 1,978 | 2,645 | 1,406 | 655.28 | - | 1,618 |
Amortization of Goodwill & Intangibles | 9.45 | 363.57 | 477.77 | 164.88 | - | 507.8 |
Other Operating Expenses | 1,277 | 922.06 | 952.7 | 970.93 | - | 278.68 |
Operating Expenses | 24,122 | 23,172 | 21,433 | 12,392 | 10,140 | 17,794 |
Operating Income | -2,870 | -4,399 | -15,158 | -9,791 | -7,914 | -9,780 |
Interest Expense | -558.39 | -559.69 | -664.06 | -3,441 | - | -2,832 |
Interest & Investment Income | 736.24 | 620.08 | 388.3 | 188.84 | - | 274.6 |
Currency Exchange Gain (Loss) | 276.53 | -827.69 | 1,153 | 1,233 | - | 25.79 |
Other Non Operating Income (Expenses) | 3,971 | -1,837 | 2,850 | 1,134 | -5,210 | -5,078 |
EBT Excluding Unusual Items | 1,555 | -7,003 | -11,431 | -10,676 | -13,125 | -17,390 |
Gain (Loss) on Sale of Investments | -3,238 | -3,601 | 849.66 | - | - | 142.54 |
Gain (Loss) on Sale of Assets | 40.86 | 2.27 | 5.54 | - | - | 610.9 |
Asset Writedown | -5,033 | -5,064 | -2,312 | - | - | -6,591 |
Other Unusual Items | - | -2.36 | -22.32 | -2,506 | - | - |
Pretax Income | -6,675 | -15,668 | -12,910 | -13,182 | -13,125 | -23,228 |
Income Tax Expense | 178.04 | -34.44 | -150.76 | - | - | 2,069 |
Earnings From Continuing Operations | -6,853 | -15,633 | -12,759 | -13,182 | -13,125 | -25,297 |
Earnings From Discontinued Operations | - | - | - | -16,992 | -3,086 | - |
Net Income to Company | -6,853 | -15,633 | -12,759 | -30,174 | -16,211 | -25,297 |
Minority Interest in Earnings | -0.06 | -0.13 | 763.26 | 10,668 | 2,346 | 5,714 |
Net Income | -6,853 | -15,634 | -11,996 | -19,506 | -13,865 | -19,582 |
Net Income to Common | -6,853 | -15,634 | -11,996 | -19,506 | -13,865 | -19,582 |
Shares Outstanding (Basic) | 119 | 113 | 103 | 78 | 72 | 70 |
Shares Outstanding (Diluted) | 119 | 113 | 103 | 78 | 72 | 70 |
Shares Change (YoY) | 8.36% | 9.70% | 32.48% | 8.49% | 2.09% | 10.20% |
EPS (Basic) | -57.81 | -138.07 | -116.23 | -250.38 | -193.08 | -278.40 |
EPS (Diluted) | -57.81 | -138.07 | -116.23 | -251.46 | -193.08 | -278.40 |
Free Cash Flow | 9,330 | 8,483 | -4,647 | -27,620 | -4,953 | -10,391 |
Free Cash Flow Per Share | 78.70 | 74.92 | -45.03 | -354.53 | -68.97 | -147.74 |
Gross Margin | 35.96% | 36.09% | 16.86% | 8.56% | 8.69% | 7.35% |
Operating Margin | -4.86% | -8.46% | -40.73% | -32.24% | -30.89% | -8.97% |
Profit Margin | -11.60% | -30.05% | -32.23% | -64.22% | -54.11% | -17.96% |
Free Cash Flow Margin | 15.79% | 16.31% | -12.49% | -90.94% | -19.33% | -9.53% |
EBITDA | 1,339 | 292.75 | -10,240 | -1,714 | -618.01 | -3,115 |
EBITDA Margin | 2.27% | 0.56% | -27.52% | -5.64% | -2.41% | -2.86% |
D&A For EBITDA | 4,210 | 4,691 | 4,918 | 8,078 | 7,296 | 6,665 |
EBIT | -2,870 | -4,399 | -15,158 | -9,791 | -7,914 | -9,780 |
EBIT Margin | -4.86% | -8.46% | -40.73% | -32.24% | -30.89% | -8.97% |
Advertising Expenses | - | 167.82 | 316.16 | 277.61 | - | 447.88 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.